Evidence map›Paper›PMID 32870371›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2021

Second primary malignancies of eye and ocular adnexa after a first primary elsewhere in the body.

Ahmad Samir Alfaar, Anas M Saad, Mahmoud Tawfik KhalafAllah, Omneya Ezzat Elsherif, Moataz Hamed Osman, Olaf Strauß

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Conjunctival cancer in people living with HIV.Current opinion in infectious diseases · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Ahmad Samir Alfaar *Experimental Ophthalmology, Department of Ophthalmology, Charité - Universitätsmedizin Berlin, a corporate member of Freie Universität, the Berlin Institute of Health, Humboldt-University, 13353, Berlin, Germany. ahmed.alfaar@medizin.uni-leipzig.de.ORCID http://orcid.org/0000-0002-0930-4583
Anas M Saad *Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID http://orcid.org/0000-0003-0101-0131
Mahmoud Tawfik KhalafAllahVision Science Graduate Program, University of Alabama, Birmingham, AL, USA.ORCID http://orcid.org/0000-0001-7973-5883
Omneya Ezzat ElsherifFamily Medicine, Cairo University Hospitals, Cairo, Egypt.ORCID http://orcid.org/0000-0002-0971-0645
Moataz Hamed OsmanOphthalmology Department, Kasr Alainy Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0000-0002-3042-8476
Olaf StraußExperimental Ophthalmology, Department of Ophthalmology, Charité - Universitätsmedizin Berlin, a corporate member of Freie Universität, the Berlin Institute of Health, Humboldt-University, 13353, Berlin, Germany.ORCID http://orcid.org/0000-0002-6272-8596
Humboldt-Universität zu Berlin · DECairo University · EGCairo University hospitals · EGCleveland Clinic · USUniversity of Alabama at Birmingham · US

Funding

Deutscher Akademischer Austauschdienst 57147166
6 · The paper itself

Abstract

purposeThe eye and its adnexal structures can give rise to first or consecutive primary malignancies or to encounter metastasis. Our aim was to define the characteristics of the second primary neoplasms affecting the eye and its adnexa and find the risk modifying factors for them after malignancies elsewhere in the body.

methodsWe have queried the Surveillance, Epidemiology and End-Results "SEER"-9 program of the National Cancer Institute for the malignancies of the eye and its adnexa that occurred between 1973 and 2015. The malignancies were ordered chronologically according to their incidence: first or second primary malignancies. The tumors were classified according to ICD-O-3 classification. Standardized incidence ratios (SIR) and survival probabilities were calculated for subgroups.

resultsAmong 3,578,950 cancer patients, 1203 experienced a second malignancies of the eye and its adnexa. The first malignancy was diagnosed between 50 and 69 years of age in 58.94% of them. The eyelid showed 280 events, while 50 in lacrimal gland, 181 in the orbit, 21 in the overlapping lesions, 15 in optic nerve, 148 in the conjunctiva, 9 in the cornea, 6 in the Retina, 379 in the choroid, and 93 in the ciliary body. The SIR of a second malignancy after a prior non-Hodgkin lymphoma was 2.42, and in case of previous skin carcinomas it was 3.02, melanoma of skin, and 2.13 and 1.58 in oral cavity/pharynx malignancies. The second ocular and adnexal neoplasms increased steadily over the 5-year periods on contrary to first primary neoplasms. The survival of patients affected with first ocular and adnexal neoplasms was significantly higher than those with second ocular and adnexal neoplasms. On the other side, second primary ocular and adnexal tumors showed a better survival than second primary malignancies elsewhere.

conclusionsThe epidemiological differences between first and second ocular and adnexal primaries suggest different underlying mechanisms. Careful ocular examination should be integrated in the long-term follow-up plan of cancer patients. Special attention should be given to patients with non-Hodgkin's lymphoma and melanoma as first primary.

Indexed as

Eye NeoplasmsLacrimal ApparatusLymphoma, Non-HodgkinNeoplasms, Second PrimaryConjunctivaHumansOrbitEpidemiologyEyeOcular adnexaOrbitSecond malignancies

Identifiers

PMID32870371
PMCPMC7843581
OpenAlexW3081666356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.